InterVenn Biosciences announces clinical data for melanoma test

By LabPulse.com staff writers

June 6, 2022 -- InterVenn Biosciences has announced clinical validation data for its Dawn IO Melanoma liquid biopsy test.

Based on glycoproteomics, the test provides insight into whether melanoma patients will benefit from immune checkpoint inhibitor therapies, the firm said.

The San Francisco-based company developed the test on its perspectIV platform, which can directly interrogate the blood glycoproteome. InterVenn conducted the validation study in collaboration with Massachusetts General Hospital on a cohort of 205 advanced melanoma patients.

ASH 2021: What technologies will disrupt hematology diagnostics?
ATLANTA - From artificial intelligence to a new genetic test that can diagnose hematological malignancies, a series of talks on the eve of the American...
Blood test shows promise for identifying cancer
A blood test that tracks microbial DNA shows promise for identifying different types of cancer based on their microbiome profiles, according to a study...
Sequencing test probes immune environment in melanoma
T-cell features outlined using Adaptive Biotechnologies' immunoSeq high-throughput DNA sequencing test have the potential to augment information about...
Genomic tests for melanoma in the spotlight
Appropriate use criteria for three gene expression profiling tests used in the management of suspicious pigmented/melanocytic lesions and biopsy-proven...
In vivo liquid biopsy method demonstrated in melanoma
Results of in vivo liquid biopsy using an investigational laser- and imaging-based platform suggest higher sensitivity for detecting circulating tumor...

Copyright © 2022 LabPulse.com

Last Updated mp 6/6/2022 3:05:57 PM